drugset
drugset / Trial / NCT07195175

Study of MAR002 in Healthy Men

NCT07195175 ↗

Phase 1 Recruiting 45 enrolled Marea Therapeutics
RandomizedSequentialTriple-blindTreatment

Summary

Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men

Timeline

Start
2025-08-11
Primary completion
2026-07
Completion
2026-07

Drugs

EvaluationDrugModalityDoseRoute
Subject MAR002 Unknown — Subcutaneous

Indications

acromegaly